Eli Lilly and Co. said its migraine drug lasmiditan met the primary and secondary endpoints in a second phase 3 study.

A greater percentage of patients treated under the study were migraine pain-free when compared to placebo and experienced no bothersome symptoms such as nausea and sensitivity to sound or light.

The most commonly reported adverse events after the drug's dosing were dizziness, paresthesia, somnolence, fatigue, nausea and lethargy.

Eli Lilly plans to submit a new drug application for lasmiditan with the U.S. Food and Drug Administration in the second half of 2018, the company said in a news release.

Findings from the study are consistent with the results from an earlier phase 3 trial.

Meanwhile, lasmiditan could potentially be paired with Lilly's chronic and episodic migraine drug galcanezumab, which met its primary endpoints in three phase 3 studies in May.